| ObjectiveTo study the clinical manifestations, related factors and therapeutic methods of Retinoic acid syndrome (RAS) during the process of Arsenic Trioxide (As2O3) treating acute promyelocytic leukemia (APL) newly-diagnosed patients.Methods56 patients with newly-diagnosed APL were given As2O3.to induce differentiation. When the WBC in peripheral blood > 20 × 109/L, 1.0-3.0g/day hydroxycarbamide was given by oral or 2mg/day homoharringtonine was given by iv. When WBC > 50× 109/L, the dose of As2O3 was reduced by half.Results12 patients among these 56 newly-diagnosed APL patients occurred RAS, occurrence rate 21.4%. 40 patients were found leukocytosis , occurrence rate 71.4%. The basic WBC value of RAS group was higher than that of the non-RAS group before the treatment (P < 0. 05) . After As2O3 treatment, WBC of RAS group was remarkably higher than that of non-RAS group (P< 0. 01) .ConclusionRAS can also be cased by applying As2O3 in the treatment of APL, and it is closely related to the leukocytosis. After symptoms appearing, combination of attenuated As2O3 and chemotoxic drugs with active supplying therapy can help most of the patients get over... |
PDF Full Text Request